Table 1b. In vitro 5-Azacytidine EC50 fold-shift enhancement by siRNA.
| Cell line |
siRNA |
||
|---|---|---|---|
| BCL-2 | BCL-XL | MCL-1 | |
| SET-2 | 1.0±0.0 (P=0.20) | 1.4±0.2 (P=0.052) | 1.1±0.1 (P=0.14) |
| TF-1 | 1.2±0.1 (P=0.011) | 3.4±0.7 (P=3.5e–5) | 1.6±0.1 (P=0.061) |
| HEL | 1.2±0.1 (P=0.38) | 4.4±1.8 (P=0.031) | 3.0±0.4 (P= 0.086) |
| THP-1 | 1.0±0.1 (P=0.82) | 1.1±0.2 (P=0.079) | 1.2±0.0 (P=0.076) |
| OCI-AML3 | 1.2±0.5 (P=0.61) | −1.1±0.2 (P=0.016) | 2.2±0.8 (P=0.056) |
| ML-2 | 1.0±0.0 (P=0.35) | 1.1±0.1 (P=0.026) | 1.4±0.0 (P=0.024) |
Anti-apoptotic BCL-2 family siRNA drug-dose-response assays with 5-Azacytidine in myeloid cells in vitro. Cell lines are listed in the left-most column. The BCL-2 family member silenced by siRNA is shown as the heading for each column. 5-Aza EC50 fold-shifts are listed with P values associated with EC50 fold-shift measurements averaged for the different siRNA sequences against each BCL-2 family member. ‘−' denotes antagonistic fold-shift.